InnoCare Pharma, a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that BTK inhibitor orelabrutinib has been granted priority review...
Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents...
AstraZeneca’s IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)...
Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION™ platforms, announces that...
